https://www.facebook.com/104644264677823/

Umesh Pd Rauniyar, Khumaltar, Lalitpur (2026)

10/08/2026

Case Study: Verghese Kurien and Amul
Many people think great brands are built by great advertising.
Verghese Kurien proved something different.
He built one of India's most trusted brands without starting as a marketer.
He started by solving a problem.
In the 1940s, millions of dairy farmers were exploited by middlemen. Farmers produced the milk but earned very little. Consumers paid more, while producers received less.
Kurien changed the entire system.
Instead of building a company around profits, he built a cooperative owned by farmers.
That cooperative became Amul.
Today, Amul is one of the largest dairy brands in the world and supports millions of farming families.
What made Amul extraordinary?
• It created value before creating a brand. • It built trust before building market share. • It ensured quality through strong systems. • It never forgot who its real stakeholders were. • Its famous "Amul Girl" campaign kept the brand relevant for decades while remaining simple and memorable.
The biggest lesson is this:
A brand becomes powerful when it improves people's lives, not just when it sells products.
Whether you work in FMCG, pharmaceuticals, or any other industry, the principle remains the same.
Strong brands are built on trust, consistency, and a clear purpose.
Products can be copied.
Advertising can be copied.
But trust built over decades cannot.
Question for leaders:
Is your brand only selling products, or is it solving a meaningful problem that customers will remember for years?

09/08/2026

Saxagliptin vs Sitagliptin:
Is Efficacy the Only Thing We Should Compare?

Both are effective DPP-4 inhibitors. Both lower HbA1c.
So why might an HCP choose one over the other?
Here are 3 clinical differences worth discussing:
1. Heart Failure: Does it change your choice?
SAVOR-TIMI 53 reported a 27% relative increase in hospitalization for heart failure with saxagliptin vs placebo. In TECOS, sitagliptin showed a neutral heart failure profile.
Does this make sitagliptin your preferred DPP-4 inhibitor in a patient with HF risk?
2. Drug Interactions: How important is CYP3A4?
Saxagliptin is affected by strong CYP3A4/5 inhibitors and requires dose adjustment in such situations.
Sitagliptin has minimal hepatic metabolism and is predominantly eliminated unchanged through the kidneys.
In patients taking multiple medications, does this difference influence your prescribing decision?
3. Renal Impairment: Which one feels simpler in practice?
Both require renal dose consideration, but saxagliptin's active metabolite and pharmacokinetic profile add another layer to the discussion.
Does sitagliptin offer a more straightforward approach when renal function is changing?
Here's the real question:
If HbA1c reduction is broadly comparable, should the decision be based on efficacy alone?
Or should we also consider:
Heart failure profile + drug interactions + renal considerations + overall patient complexity?
HCPs, what's your experience?
If you had to choose between Saxagliptin and Sitagliptin for a patient with multiple comorbidities and polypharmacy, which would you choose and why?
I'd particularly like to hear perspectives from endocrinologists, diabetologists, cardiologists and clinical pharmacists.

09/08/2026

Before You Build the Plant, Build the Market.
For upcoming pharmaceutical companies, success does not begin when the plant is ready, it begins much earlier.
Land, machinery, construction, and regulatory approvals are essential. But without the right product portfolio, clear therapy focus, and strong brand positioning, even a well-equipped plant can enter the market with avoidable risk.
We believe in one principle:
Market First, Then Manufacture.
This approach is valuable not only for new ventures, but also for companies that are:
• Preparing to launch in the near future
• Recently launched but struggling to gain market traction
• Facing weak brand differentiation or slow doctor acceptance
• Carrying an overcrowded or low-performing product portfolio
By planning products, mapping competition, refining positioning, preparing the field force, and creating a focused launch roadmap, companies can build stronger momentum.
The outcome:
• Faster and more confident market entry
• Stronger brand differentiation
• Better doctor acceptance
• Smarter product investment
• Sustainable long-term growth
The best investment is not only in buildings and machines. It is in choosing the right products and building brands the market will value.

07/08/2026

Nepal has just sent a powerful message to the world.
Shinta Mani Mustang, a 29 room luxury retreat in the Kali Gandaki Valley near Jomsom, has been ranked the World's No. 1 Luxury Hotel in Robb Report's 50 Greatest Luxury Hotels on Earth 2026.
Think about that for a moment.
A destination in one of the most remote regions of the Himalayas has surpassed iconic luxury hotels in Paris, Dubai, and the Swiss Alps.
The real story is not the award. It is the strategy behind it.
There was no massive government incentive package, no aggressive international campaign, and no extraordinary policy support. What made the difference was a clear vision, unwavering commitment to quality, respect for local culture, and flawless ex*****on.
This success carries an important lesson for every Nepali entrepreneur.
We often blame the market, policy, or competition for our limitations. But sustainable success rarely comes from perfect conditions. It comes from creating exceptional value that the world cannot ignore.
If one hospitality project in Mustang can become the world's best, what is stopping other Nepali businesses from building brands that earn global respect?
Nepal has the resources. What we need is more vision, more courage, and an uncompromising commitment to excellence.
Congratulations to the entire team behind this remarkable achievement. You have not only elevated Nepali hospitality but also strengthened the global image of Nepal.

05/08/2026

Congratulations and best wishes Dr. Kadir Alam for being appointed as the Chairman of the Nepal Pharmacy Council by Nepal Government.

05/08/2026

Nepal's pharmaceutical market has crossed NPR 7,600 crore. That's the headline.
The bigger question is:
Are companies growing because the market is growing, or because they have a winning strategy?
According to the IQVIA Nepal Market Reflection Report (June 2026), the market reached NPR 7,615 crore, growing 7% MAT, while June itself recorded an impressive 14% year-on-year growth.
A few observations stand out:
• Acute therapies continue to drive volumes, but chronic therapy categories such as Rosuvastatin, Amlodipine + Losartan, and Metformin + Sitagliptin are showing healthy growth.
• The competitive landscape is changing. Companies that are investing in focused portfolios, strong ex*****on, and consistent brand building are pulling ahead.
• Double digit market growth is an opportunity, but only for organizations that can execute consistently. A growing market does not automatically create market leaders.
As Nepal prepares for increasing competition in the coming years, success will depend less on expanding product lists and more on:
✔ Strong portfolio strategy
✔ Scientific brand positioning
✔ Capability building of the field force
✔ Better ex*****on at every level
Markets create opportunities.
Ex*****on creates leaders.
What do you think will be the biggest growth driver for Nepal's pharmaceutical industry over the next five years: innovation, ex*****on, or market expansion?

02/08/2026

The Man Who Built India's Biggest Beverage Brands... Yet Few Know His Name
Most people know Thums Up, Limca, Maaza, and Bisleri.
Very few know the man behind them:
Ramesh J. Chauhan.
His story isn't just about creating brands. It's about seeing opportunities before everyone else.
Phase 1: Turning a Crisis into an Opportunity (1977)
In 1977, Coca-Cola exited India after refusing to comply with government regulations.
Many saw it as a market collapse.
Ramesh Chauhan saw an empty playground.
Instead of waiting for another multinational to return, he quickly launched Indian alternatives.
• Thums Up for cola lovers • Limca for lemon-lime refreshment • Maaza for fruit drink lovers
He didn't just replace Coca-Cola. He built brands that became household names across India.
Lesson: Great entrepreneurs don't complain about market gaps. They fill them.
Phase 2: Knowing When to Sell (1993)
When Coca-Cola returned to India in 1993, it had deep pockets, global expertise, and unmatched distribution power.
Many entrepreneurs would have fought a long and expensive battle.
Chauhan chose a different path.
He sold Thums Up, Limca, Maaza, Citra, and Gold Spot to Coca-Cola for a landmark deal.
At first glance, it looked like he had exited.
In reality, he had simply changed the game.
Lesson: Winning isn't always about holding on. Sometimes it's about knowing the right time to let go.
Phase 3: Betting on Something Nobody Wanted
After selling his soft drink empire, he focused on Bisleri.
At that time, selling bottled drinking water sounded absurd.
People asked:
"Who will ever pay for water?"
Chauhan believed that rising urbanisation, health awareness, travel, and concerns about water quality would create a completely new market.
He wasn't selling water.
He was selling trust, hygiene, safety, and convenience.
The rest is history.
Bisleri became synonymous with packaged drinking water in India.
Leadership Takeaways
• Spot opportunities where others see uncertainty. • Build strong brands, not just products. • Know when to compete and when to exit. • Reinvent yourself before the market forces you to. • The biggest businesses are often created by solving problems people don't yet recognise.
Ramesh J. Chauhan reminds us that true entrepreneurs don't just build companies.
They build markets.
And sometimes, the greatest business legends remain the least celebrated.

30/07/2026

Clinical Choice | Part 4 (Final)
Beyond Diabetes
Has the role of SGLT2 inhibitors fundamentally changed?
A decade ago, SGLT2 inhibitors were prescribed primarily to lower blood glucose.
Today, they have become an integral part of cardiorenal protection, benefiting patients with:
• Type 2 Diabetes • Heart Failure • Chronic Kidney Disease • With or without diabetes, depending on the indication
The conversation has evolved from:
"Which SGLT2 inhibitor lowers HbA1c better?"
to
"Which patient will benefit most from an SGLT2 inhibitor?"
Perhaps this is the most important shift in modern medicine.
The patient now comes before the molecule.
As we conclude this series, I'd like to ask one final question.
Has your prescribing approach to SGLT2 inhibitors changed over the past five years? If yes, what has been the biggest driver of that change?
Thank you to everyone who contributed thoughtful comments throughout this series. Your insights made the discussion richer and more meaningful.

29/07/2026

Forever grateful to every Guru whose wisdom, guidance, and blessings have shaped my journey. Happy Guru Purnima! 🙏

28/07/2026

Series: Clinical Choice | Part 3
T2DM + Chronic Kidney Disease
Which SGLT2 inhibitor do you prefer?
The role of SGLT2 inhibitors in CKD has transformed the management of patients with Type 2 Diabetes.
Both Empagliflozin and Dapagliflozin have demonstrated substantial renal and cardiovascular benefits. Landmark trials such as DAPA-CKD and EMPA-KIDNEY have reinforced their role in slowing CKD progression and reducing cardiorenal events.
Yet, in everyday clinical practice, several factors may influence the choice, including:
• CKD stage and eGFR
• Albuminuria (UACR)
• Coexisting Heart Failure or ASCVD
• Guideline recommendations
• Drug availability and affordability
• Individual clinical experience
There is no one-size-fits-all answer. The optimal choice depends on the patient sitting in front of us.
I'm interested to hear from diabetologists, endocrinologists, nephrologists, cardiologists, and physicians.
In a patient with Type 2 Diabetes and CKD, which SGLT2 inhibitor do you prefer, and what is the key factor behind your decision?

Umesh Pd Rauniyar

10/08/2026

09/08/2026

09/08/2026

07/08/2026

05/08/2026

05/08/2026

02/08/2026

30/07/2026

29/07/2026

28/07/2026

Address

Website

Alerts

Shortcuts

Share

Category

Listing takedown request